Oral iron chelation therapy for thalassaemia: an uncertain scene. Annotation
- 1 October 2000
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 111 (1), 2-5
- https://doi.org/10.1046/j.1365-2141.2000.02406.x
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Safety profile of the oral iron chelator deferiprone: a multicentre studyBritish Journal of Haematology, 2000
- Iron Chelation with Oral Deferiprone in Patients with ThalassemiaNew England Journal of Medicine, 1998
- Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia MajorNew England Journal of Medicine, 1998
- Iron-Chelation Therapy with Oral Deferiprone — Toxicity or Lack of Efficacy?New England Journal of Medicine, 1998
- An Orally Active Iron ChelatorNew England Journal of Medicine, 1995
- Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia MajorNew England Journal of Medicine, 1995
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorNew England Journal of Medicine, 1994
- Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trialBritish Journal of Haematology, 1992
- Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patientsThe Lancet, 1990
- 2 The development of iron chelating drugsBailliere's Clinical Haematology, 1989